H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-20 08:00
Regulatory News Service
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB
2025-02-05 07:46
Annual Report
English 6.4 MB
2025-02-05 07:46
Report Publication Announcement
English 2.9 KB
2025-02-05 07:46
Annual Report (ESEF)
English 13.1 MB
2025-02-05 07:24
Earnings Release
English 33.3 KB
2025-02-05 07:24
Earnings Release
English 443.0 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Dottikon ES Holding AG Logo
Exclusive synthesis of APIs & fine chemicals via hazardous reactions for pharma/biotech industries.
Switzerland DESN
Double Bond Pharmaceutical International AB Logo
Redeveloping drugs with proprietary delivery tech for oncology & infectious diseases.
Sweden DBP B
Develops & commercializes PET/CT tracers for diagnosing cancer & neurological disorders.
South Korea 176750
Dx & Vx Co., Ltd. Logo
Develops innovative diagnostics & vaccines and provides comprehensive life science contract services.
South Korea 180400
Manufactures vet pharma for livestock/aquaculture & distributes premium pet food.
South Korea 044960
ECO ANIMAL HEALTH GROUP PLC Logo
Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.
United Kingdom EAH
Ectin Research AB Logo
Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.
Sweden ECTIN B
Eevia Health Plc Logo
Manufactures validated polyphenol extracts from Arctic plants for the supplement & food industries.
Finland EEVIA
Egetis Therapeutics Logo
Develops and commercializes drugs for serious rare diseases with unmet medical needs.
Sweden EGTX
EIKEN CHEMICAL CO.,LTD. Logo
Manufacturer of clinical diagnostics, specializing in FIT systems for cancer and microbiological tests.
Japan 4549

Talk to a Data Expert

Have a question? We'll get back to you promptly.